Skip to search boxSkip to navigationSkip to main content

Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru

  • Abraham De-Los-Rios-Pinto
    ,
  • ,
  • David R. Soriano-Moreno
    ,
  • Lucero Sangster-Carrasco
    ,
  • Noelia Morocho-Alburqueque
    ,
  • Antony Pinedo-Soria
  • Universidad Nacional de San Antonio Abad del Cusco
    ,
  • ,
  • Universidad Peruana Union
    ,
  • Universidad Peruana de Ciencias Aplicadas
    ,
  • Universidad Nacional de Piura
    ,
  • Universidad Nacional de San Martín
Research Output:
Contribution to journal
Article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 3566-3572 (7 pages)

Journal (Volume, Issue Number)

Vaccine (Volume 40, Issue 26)

Publication milestones

  • Published - 09/06/2022

Publication status

Published - 09/06/2022

ISSN

0264-410X

Publication IDs

  • Scopus: 85130398533
  • PubMed: 35589452

Abstract

Objective: To evaluate the factors associated with the intention to participate in COVID-19 vaccine clinical trials in the Peruvian population. Methods: Cross-sectional study and secondary analysis of a database that involved Peruvian population during September 2020. The Poisson regression model was used to estimate the associated factors. Results: Data from 3231 individuals were analyzed, 44.1% of whom intended to participate in COVID-19 vaccine clinical trials. Factors associated with the outcome were being male (RPa: 1.25; 95% CI: 1.15–1.35), being from the highlands region (RPa: 1.18; 95% CI: 1.09–1.28) or jungle (RPa: 1.30; 95% CI: 1.15–1.47), having a relative that is a healthcare professional (PRa: 1.16; 95% CI: 1.06–1.28), using a medical source of information (PRa: 1.28; 95% CI: 1.17–1.41), and trusting in the possible effectiveness of vaccines (PRa: 1.40; 95% CI: 1.29–1.51). The main reason for not participating in the trial was the possibility of developing side effects (69.80%). Conclusion: There is an urgent need to generate a perception of safety in COVID-19 vaccine clinical trials, to increase the population's intention to participate in these studies, and to provide evidence-based information about the vaccine.

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Social media
21
Captures
40
Citations
3

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well